Top Page
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
(1541)
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) vs. iShares MSCI Hong Kong ETF (EWH)
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Business Overview & Revenue Model
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 122.83M | 74.15M | 386.00K | 5.69M | 13.81M |
| Gross Profit | 122.83M | 74.15M | 7.70M | 5.69M | 13.81M |
| EBITDA | -300.82M | -295.63M | -355.35M | -384.49M | -718.88M |
| Net Income | -302.68M | -315.86M | -379.46M | -402.89M | -732.95M |
Balance Sheet | |||||
| Total Assets | 771.24M | 922.00M | 874.59M | 839.98M | 892.84M |
| Cash, Cash Equivalents and Short-Term Investments | 703.70M | 752.12M | 608.56M | 635.21M | 668.33M |
| Total Debt | 153.72M | 136.36M | 74.77M | 14.62M | 18.54M |
| Total Liabilities | 237.36M | 243.69M | 126.30M | 60.76M | 2.49B |
| Stockholders Equity | 534.62M | 678.90M | 748.29M | 779.22M | -1.60B |
Cash Flow | |||||
| Free Cash Flow | -140.89M | -138.44M | -370.25M | -261.93M | -315.79M |
| Operating Cash Flow | -136.13M | -128.03M | -367.55M | -238.71M | -190.54M |
| Investing Cash Flow | 42.88M | 37.95M | -294.85M | 49.00K | -108.72M |
| Financing Cash Flow | 253.48M | 258.93M | 331.04M | 179.38M | 793.03M |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Technical Analysis
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$12.07B | 84.43 | 16.13% | ― | 48.38% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$9.23B | -32.42 | -12.74% | ― | -76.58% | -4.90% | |
42 Neutral | HK$8.81B | -19.44 | -95.84% | ― | -55.64% | -158.67% | |
41 Neutral | HK$7.25B | -10.69 | -53.23% | ― | 29639.67% | 23.30% | |
40 Underperform | HK$10.56B | -50.44 | -21.42% | ― | 240.05% | -140.09% |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Corporate Events
ImmuneOnco Biopharmaceuticals has announced the redemption of two wealth management products totaling HK$93,323,273 from Huatai Financial, resulting in an estimated unaudited gain of HK$4,730,000. The company has also subscribed to a new wealth management product worth HK$120,000,000, funded by its internal surplus cash reserves. These transactions are classified as discloseable under the Hong Kong Stock Exchange’s listing rules, requiring notification and announcement but exempt from shareholder approval.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced amendments to its Articles of Association following the completion of a placement of new H shares, which increased the company’s total issued shares. This adjustment in the share capital structure reflects the company’s strategic efforts to enhance its market presence and operational capacity, potentially impacting its stakeholders by aligning its governance documents with its expanded capital base.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announced that Dr. Tian Wenzhi, the company’s executive director, CEO, and chairman, has increased his shareholding by purchasing 50,000 H shares on the open market. This purchase reflects Dr. Tian’s confidence in the company’s growth prospects, as he now holds 26.90% of the total issued share capital. The move is seen as a positive signal to shareholders and potential investors about the company’s future potential.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
ImmuneOnco Biopharmaceuticals has successfully dosed the first patient in a Phase IB/II clinical trial for its cancer treatment combination of IMM2510 and IMM01, marking a significant milestone in cancer immunotherapy. This development could enhance the company’s industry positioning by showcasing its innovative approach to cancer treatment, potentially impacting stakeholders positively.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has successfully completed the placement of 24.2 million new H shares, raising approximately HK$345.1 million. The proceeds will be used to fund research and development of cancer therapies, including IMM2510, IMM27M, and IMM01, as well as to replenish working capital and support general corporate purposes.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc announced a placement of 24,200,000 new H shares at HK$14.50 per share, representing approximately 5.94% of the company’s issued share capital. The placement is expected to raise gross proceeds of approximately HK$350.9 million, with net proceeds estimated at HK$345.1 million. The shares will be placed to at least six independent third-party investors, and the placement does not require shareholders’ approval as it falls under the general mandate granted by the company’s shareholders. This move is part of the company’s strategy to strengthen its financial position and support its ongoing operations and development projects.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
ImmuneOnco Biopharmaceuticals has announced the submission of a Phase III clinical trial application for IMM2510, targeting immunotherapy-resistant non-small cell lung cancer. The trial aims to verify the efficacy and safety of IMM2510, which has shown promising results in earlier studies, including a 35.3% objective response rate and a 76.5% disease control rate in patients with advanced squamous NSCLC. This development could enhance the company’s position in the oncology market by offering a potentially effective treatment option for lung cancer patients.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the submission of an application for a Phase III clinical trial of IMM0306, a bispecific molecule targeting CD47 and CD20, for the treatment of follicular lymphoma. This development marks a significant step as IMM0306 is the first dual-targeting bispecific molecule of its kind to reach the clinical stage globally, potentially enhancing the company’s position in the oncology market by offering improved therapeutic outcomes for patients.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
ImmuneOnco Biopharmaceuticals announced its unaudited consolidated interim results for the first half of 2025, highlighting significant progress in its oncology drug pipeline. The company completed patient enrollment and achieved primary endpoints in Phase II clinical trials for its core product, IMM01, in combination with azacitidine for treating higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia, demonstrating promising efficacy and tolerability.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.